Development and Validation of an Immune-Related Prognostic Signature for Laryngeal Squamous Cell Carcinoma
Journal of Clinical Medicine · 09.07.2026 · 15 (14) · 5382
DOI: 10.3390/jcm15145382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 09.07.2026. Verfasst von Changding He und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhongshan Hospital, Shanghai Minhang District Leading Talent Project, Shanghai Pudong New Area Health Commission.
Abstract (Originalsprache)
Background
Laryngeal squamous cell carcinoma (LSCC) is a highly aggressive malignancy with poor prognosis, particularly in advanced stages. While traditional treatments have improved survival rates, reliable biomarkers for prognosis remain limited.
Methods
We analyzed RNA-seq data of LSCC patients from the Cancer Genome Atlas (TCGA) and validated the results using the Gene Expression Omnibus (GEO) dataset (GSE27020), clinical samples, and LSCC cell lines. Differentially expressed immune-related genes (DEIRGs) were identified using the “limma” R package. A prognostic signature was developed by integrating univariate Cox analysis, least absolute shrinkage and selection operator (LASSO) regression, and multivariate Cox analysis. The signature’s predictive performance was validated using Kaplan–Meier survival analysis and receiver operating characteristic (ROC) curves.
Results
A three-gene immune-related prognostic signature comprising TNFRSF4, PPARG, and PDGFA was established. In the training cohort, the model stratified patients into high- and low-risk groups with significantly different overall survival (HR = 5.81, 95% CI: 2.56–13.22, p < 0.001), with apparent 1-, 2-, and 3-year AUC values of 0.838, 0.895, and 0.947, respectively. Predictive performance was further evaluated in the TCGA testing cohort, the full TCGA cohort, and the GSE27020 cohort. Functional enrichment analysis revealed that the signature genes are involved in immune regulation and tumor progression.
Conclusions
This study identified and validated a novel three-gene immune-related prognostic signature for LSCC, offering a practical tool for individualized prognosis and personalized treatment strategies. The signature provides insights into immune-related mechanisms in LSCC, presenting potential targets for therapeutic intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China.
- Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Department of Clinical Laboratory, Punan Branch of Renji Hospital, Shanghai Jiao Tong University, Shanghai 201312, China.
ORCID-Profile: Wanqiu Peng
Förderung
- Zhongshan Hospital
- Shanghai Minhang District Leading Talent Project
- Shanghai Pudong New Area Health Commission
- Science and Technology Development Fund of Pudong New District Minsheng Scientific Research (Medical and Health) Project
- Zhongshan Hospital, Fudan University
Zitieren
APA
He, C., Peng, W., Shi, Y., & Du, H. (2026). Development and Validation of an Immune-Related Prognostic Signature for Laryngeal Squamous Cell Carcinoma. Journal of Clinical Medicine, 15(14), 5382. https://doi.org/10.3390/jcm15145382
Vancouver
He C, Peng W, Shi Y, Du H. Development and Validation of an Immune-Related Prognostic Signature for Laryngeal Squamous Cell Carcinoma. Journal of Clinical Medicine. 2026;15(14):5382. doi:10.3390/jcm15145382
BibTeX
@article{He2026,
author = {He, Changding and Peng, Wanqiu and Shi, Yi and Du, Huaidong},
title = {Development and Validation of an Immune-Related Prognostic Signature for Laryngeal Squamous Cell Carcinoma},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {14},
pages = {5382},
doi = {10.3390/jcm15145382}
}
EUVIMED